Antibody-drug conjugate · Kills target cells, directed at carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) · developed by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Precemtabart tocentecan is an antibody-drug conjugate made of a human IgG1 monoclonal antibody against CEACAM5, linked to the topoisomerase I inhibitor exatecan. After the antibody binds CEACAM5 on tumor cells and is internalized, exatecan is released and disrupts DNA replication, causing cell cycle arrest and apoptosis. It is being studied in solid tumors and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
Colorectal CancerSolid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →